Tata Small Cap Fund-Held Pharma Stock Jumps 9% as Bengaluru API Facility Secures Swiss GMP Certification

Hikal Limited is seeking to build a more pharma-led business mix through active pharmaceutical ingredients, contract development and manufacturing services, and specialised chemistry platforms. Its Bengaluru active pharmaceutical ingredient facility has now received a Certificate of Good Manufacturing Practice (GMP) Compliance of a Manufacturer from SwisSMEdic, the Swiss Agency for Therapeutic Products.

The certification, announced on October 30, 2026, confirms that the facility meets GMP requirements under the Mutual Recognition Agreement between the European Union and Switzerland. This recognition strengthens the site’s regulatory credentials and can support Hikal’s engagement with customers in Europe and other tightly regulated pharmaceutical markets.

The Bengaluru facility had earlier undergone inspections by Brazil’s ANVISA and Japan’s PMDA. The latest Swiss recognition adds to the site’s regulatory track record at a time when pharmaceutical manufacturers are placing greater importance on compliant, multi-region supply chains and dependable manufacturing partners.

For Hikal, the development is strategically relevant because pharmaceuticals remain its larger operating segment. The business reported consolidated pharmaceutical revenue of Rs 1,021 crore in FY2025-26, although this was down 12.6 per cent from the preceding year amid regulatory headwinds and weaker customer ordering in the earlier part of the year. The pharmaceutical segment’s result fell to Rs 32.8 crore from Rs 137.4 crore.

Management has been expanding its capabilities in complex chemistry, high-potency active pharmaceutical ingredients and contract development and manufacturing programmes. It has also positioned geographic diversification as a way to reduce exposure to geopolitical and trade disruptions. Chairman and Managing Director Sameer Hiremath said the Swissmedic certification endorses the quality systems at the Bengaluru facility and creates opportunities to expand customer relationships in Europe and other regulated markets.

Mutual funds collectively hold a 5.09 per cent stake in the company, representing 62.79 lakh shares. Tata Mutual Fund’s Tata Small Cap Fund holds a 2.68 per cent stake, equivalent to 33 lakh shares, while ICICI Prudential Healthcare Fund holds 2.41 per cent, representing 29.77 lakh shares.

As of 9:57 am on October 30, 2026, Hikal shares were trading at Rs 223. The stock was up 8.91 per cent from its previous close. 

What This Means for Investors

The Swissmedic certification is supportive of Hikal’s effort to strengthen its pharmaceutical franchise beyond domestic and less-regulated markets. It improves the Bengaluru facility’s credibility with regulated-market customers and complements earlier inspections by Brazilian and Japanese regulators. This matters because Hikal is pursuing higher-value active pharmaceutical ingredient and contract manufacturing programmes, where compliance history can influence customer qualification and product sourcing decisions.

The financial benefit will depend on conversion into incremental customer approvals, product filings and commercial volumes. Certification alone does not immediately change revenue or profitability, particularly after pharmaceuticals recorded weaker FY2025-26 sales and segment profitability. Hikal generated Rs 302.1 crore of operating cash flow during the year and reduced aggregate borrowings, providing some support for continued capability investment. The main execution watchpoint remains the pace at which regulatory recognition translates into sustained utilisation, better product mix and margin recovery in the pharmaceutical business.

Disclaimer: The article is for informational purposes only and not investment advice.